Available Technologies
# of Displayed Technologies: 4 / 4
Applied Category Filter (Click To Remove): Clinical Area
Targeting Telomerase to Treat Ocular Neovascular Disorders
TS-065809 — Therapeutic strategies for treating ocular neovascular disorders by targeting telomerase.
Choroidal neovascularization (CNV) is the principal driver of blindness in neovascular age-related macular degeneration (nvAMD). Abnormal blood vessel growth beneath the macular leads to retinal damage and severe vision loss. Discovering the involvement of VEGF in the underlying mechanisms driving …
- College: College of Medicine (COM)
- Inventors: Kerur, Nagaraj
- Licensing Officer: Schultz, Teri
How Are You Feeling Today? Organizational Mental Health Indicator and Real-Time Help Application
TS-064244 — The Need: Organizations, particularly college campuses, are facing a growing challenge in addressing student mental health issues. The rising prevalence of severe psychological problems, anxiety disorders, and depression among students necessitates a proactive and effective solution. The existing ga…
- College: College of Engineering (COE)
- Inventors: Ezell, Jonathan; Kaufman, Michael
- Licensing Officer: Dahlman, Jason "Jay"
Unleashing the Power of Radiotherapy - Enhancing Tumor Oxygenation with Next-Gen Radiosensitizers
TS-062384 — , T2018-092, T2018-354, & T2020-216 This technology provides novel radiosensitizer compounds that are derivatives of papaverine designed to enhance tumor oxygenization without PDE-related side effects.
Papaverine is an FDA-approved phosphodiesterase 10A (PDE10A) inhibitor and its clinical use is due to these effects on blood pressure and vascular tone. However, it was found to also be a potent inhibitor of mitochondrial complex I. Papaverine’s mitochondrial complex I inhibition has been sho…
- College: College of Medicine (COM)
- Inventors: Denko, Nicholas; Benej, Martin; Haines, Ben; Mitton-Fry, Mark
- Licensing Officer: Schultz, Teri
LNA Inhibitor Cocktail Therapy for Lupus
TS-037260 — A cocktail of locked nucleic acids inhibits the inflammatory response in a humanized murine model of lupus.
Systemic lupus erythematosus (SLE) is an orphan disease affecting approximately 5 in every 10,000 individuals. Despite its rare prevalence, this lifelong autoimmune disease has few effective targeted therapies. Current treatments are palliative using anti-inflammatory drugs or broad spectrum immun…
- College: College of Medicine (COM)
- Inventors: Jarjour, Wael; Valiente, Giancarlo; Young, Nicholas
- Licensing Officer: He, Panqing
